Abstract
Streptococcus pneumoniae is a leading cause of invasive and noninvasive bacterial infections in infants and young children. Reported incidence of pneumococcal disease varies by age, genetics, and geographic location; geographic differences may also be affected by variations in blood culturing practices. Pneumococcal serogroups 6, 9, 14, 18, 19, and 23 are commonly responsible for causing considerable invasive disease in Europe. The pneumococcal saccharide conjugated vaccine, adsorbed 1 1 Trademark: Prevenar ® (Wyeth Lederle Vaccines SA, Louvain-la-Neuve, Belgium). (PNCRM7) is the first commercially available pneumococcal conjugate vaccine proven to prevent invasive disease in infants and young children. In Europe, this vaccine may prevent a greater proportion of the overall pneumococcal disease burden than would have been previously anticipated based on the available epidemiologic data
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
